Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy

Figure 1

Overview of patient data from an investigation of the concordance of 106 primary CRCs and 270 corresponding metastases syn-/metachronic metastases. Each line represents an individual patient with primary CRC and metastatic manifestations. Red bars demonstrate KRAS mutation positive CRCs (𝑛 = 42) with corresponding lymph node metastases (𝑛 = 26), liver metastases (𝑛 = 40), lung metastases (𝑛 = 22), and other sites (𝑛 = 18) including bone marrow (𝑛 = 6), soft tissue (𝑛 = 5), and peritoneum (𝑛 = 7). Green bars show KRAS mutation negative CRCs (𝑛 = 63) with corresponding lymph node metastases (𝑛 = 43), liver metastases (𝑛 = 61), lung metastases (𝑛 = 28), and other sites (OS) (𝑛 = 32) including bone marrow (𝑛 = 10), soft tissue (𝑛 = 13) and peritoneum (𝑛 = 9). In case #43 a heterogeneously differentiated primary CRC (see also Figure 2) showed a KRAS mosaicism (red and green bars in pCRC) with detection of KRAS mutation G12V in other sites (OS, undifferentiated soft tissue und peritoneal metastases (red bars)) but not in moderately differentiated lymph node and liver metastases (LN and LI, green bars). LN: lymph node; LI: liver; LU: lung; OS: other sites.